CAS No. |
51-77-4 |
中文名称 |
(4E,8E)-5,9,13-三甲基十四碳-4,8,12-三烯酸(E)-3,7-二甲基辛-2,6-二烯-1-基酯 |
英文名称 |
(E)-3,7-dimethylocta-2,6-dien-1-yl (4E,8E)-5,9,13-trimethyltetradeca-4,8,12-trienoate |
别名 |
AKOS015966756 | gefarnate | UNII-1ISE2Y6ULA | [(2E)-3,7-dimethylocta-2,6-dienyl] (4E,8E)-5,9,13-trimethyltetradeca-4,8,12-trienoate | 111GE003 | DTXCID7028562 | Gefarnyl | Gefarnato | GEFARNATE [INN] | 4,8,12-Tetradecatrienoic acid, 5,9,13-trimethyl-, (2E |
标准英文名 |
(E)-3,7-dimethylocta-2,6-dien-1-yl (4E,8E)-5,9,13-trimethyltetradeca-4,8,12-trienoate |
MDL No. |
MFCD00129086 |
分子式 |
C27H44O2 |
分子量 |
400.65
|
精确分子量 |
400.33
|
SMILES |
CC(C)=CCC/C(C)=C/CC/C(C)=C/CCC(=O)OC/C=C(\C)CCC=C(C)C |
标准SMILES |
C/C(/CC/C=C(\C)/CCC=C(C)C)=C\CCC(=O)OC/C=C(\C)/CCC=C(C)C |
用途 |
Gefarnate is primarily used for the treatment of acute and chronic gastritis, as well as gastric and duodenal ulcers. It accelerates metabolism, regulates gastrointestinal function and gastric acid secretion, and enhances mucosal protection. It is also currently under investigation for the treatment of dry eye disease. In vitro studies show that gefarnate (at concentrations of 0.001, 0.01, or 0.1 mg/mL) increases mucin-like glycoprotein secretion in a dose-dependent manner, with a statistically significant effect observed only at 0.1 mg/mL. Gefarnate specifically stimulates mucin-like glycoprotein secretion. |
InChIKey |
ZPACYDRSPFRDHO-ROBAGEODSA-N |